Once-Monthly Risedronate Effective Against OsteoporosisNote : No abstract availableKatherine KahnDVM
·Bisphosphonates include alendronate 10 mg or risedronate 5 mg orally once daily, alendronate 70 mg or risedronate 35 mg orally once weekly, risedronate or ibandronate 150 mg orally once monthly, or zoledronic acid 5 mg IV once yearly. ·Dosing is the same for those patients with asymptomatic ...
BACKGROUND: Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment... KG Saag,SH Gehlbach,JR Curtis,... - 《N Engl J Med》 被引量: 3499发表: 1998年 The Epidemiology of Corticosteroid-Induced Osteoporosis:...
Article CAS PubMed Google Scholar Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General (Office of the Surgeon General, 2004). Hernlund, E. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report...
Brown JP, Kendler DL, McClung MR, et al. 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–111. ArticlePubMedCASGoogle Scholar Harris ST, Watts NB, Genant HK, et al. 1999 Effects of risedronate treatment...
The recommended dosing schedule for alendronate is once daily to once weekly, for risedronate once weekly to once monthly, for ibandronate once every three months intravenously or once a month orally, and for zoledronate once a year intravenously (6–9). Interestingly, the frequency of dosing ...
N Engl J Med 2000; 343: 604–610. 44 Orwoll ES, Miller P, Adachi J et al. Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-...
Toremifene is a SERM approved for the treatment of advanced breast cancer. Toremifene is also being developed for the treatment of osteoporosis and other complications associated with hormone therapy for prostate cancer. In a 6-month, placebo-controlled study, 46 men with prostate cancer who were ...
770-P: Treatment Satisfaction and Fear of Hypoglycemia in the ADAPT Study: A Six-Month, Randomized Controlled Trial Comparing an Advanced Hybrid Closed-Loo... Objective: To assess the effect of the MiniMed 780G Advanced Hybrid Closed Loop (AHCL) system compared to MDI with isCGM (MDI+isCGM...
(200 µg mL− 1) through intraperitoneal injection every two days for a total of four weeks. Over eight weeks, the body weight of animals was recorded once a week. At the endpoint, all mice were euthanized by inhalation of isoflurane after diverse treatments, and then the muscles, ...